GUIDANCE DOCUMENT
Diabetic Foot Infections: Developing Drugs for Treatment October 2023
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2023-D-4067
- Issued by:
-
Guidance Issuing OfficeCenter for Drug Evaluation and Research
The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of diabetic foot infections (DFIs) without concomitant bone and joint involvement. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the overall development program and clinical trial designs for the development of drugs to support an indication for treatment of DFI. Development of drugs for the treatment of acute bacterial skin and skin structure infections, defined as cellulitis/erysipelas, wound infection, and major cutaneous abscess, is addressed in a separate guidance.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2023-D-4067.